Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALS
ALS
AcuraStem and Takeda Partner to Revolutionize ALS Treatment
Best Stocks
Mon, 09/25/23 - 07:40 pm
Takeda
AcuraStem
ALS
AS-202
FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show
BioPharma Dive
Mon, 09/25/23 - 11:52 am
Brainstorm Cell Thearpaueics
ALS
stem cells
FDA
NurOwn
ALS advocates say criticism of new drugs misses bigger picture
Stat
Fri, 09/8/23 - 10:18 am
ALS
drug development
Clene polishes tarnished ALS asset with long-term survival data
Fierce Biotech
Tue, 08/29/23 - 11:25 am
Clene
ALS
clinical trials
CNM-Au8
Amylyx ALS drug sales tick higher after fast US launch
BioPharma Dive
Mon, 08/14/23 - 10:22 am
Amylx
earnings
ALS
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
Mon, 07/24/23 - 09:57 am
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Fierce Biotech
Fri, 07/7/23 - 08:40 am
BrainStorm Cell Therapeutics
ALS
cell therapy
Biogen
NurOwn
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's ALS Treatment
Benzinga
Fri, 06/23/23 - 09:51 am
Amylyx Pharmaceuticals
ALS
Albrioza
EMA
Europe
Biogen teams with NeuroSense to explore ALS neurofilament biomarker
BioSpace
Wed, 06/14/23 - 11:35 am
Biogen
NeuroSense Therapeutics
ALS
PrimeC
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
Forbes
Mon, 06/12/23 - 10:08 am
clinical trials
innovation
ALS
Parkinson's Disease
Biogen
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
BioPharma Dive
Tue, 06/6/23 - 04:11 pm
BrainStorm Cell Therapeutics
FDA
NurOwn
cell therapy
ALS
Quanterix sees a bright future for blood biomarkers
EP Vantage
Fri, 06/2/23 - 10:08 am
Biogen
Quanterix
diagnostics
Qalsody
ALS
biomarkers
Amylyx’s ALS drug could face rejection in Europe
BioPharma Dive
Wed, 05/31/23 - 10:45 am
Amylyx
ALS
EMA
Europe
Relyvrio
Apellis abandons ALS drug after study miss
BioPharma Dive
Thu, 05/25/23 - 01:16 pm
Apellis Pharmaceuticals
ALS
clinical trials
pegcetacoplan
Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target
Fierce Biotech
Tue, 05/23/23 - 11:41 am
Wave Life Sciences
antisense
WVE-004
clinical trials
ALS
dementia
Amylyx’s ALS drug Relyvrio generates $71.4M in Q1
Medical Marketing and Media
Mon, 05/15/23 - 10:14 am
Amylyx Pharmaceuticals
ALS
earnings
Relyvrio
Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?
BioSpace
Thu, 04/27/23 - 11:51 am
Biogen
Qalsody
tofersen
ALS
drug development
R&D
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Medical Marketing and Media
Tue, 04/25/23 - 10:20 pm
Biogen
Ionis Pharmaceuticals
ALS
tofersen
FDA
As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate
Clinical Trials Arena
Mon, 04/24/23 - 11:23 am
Cytokinetics
clinical trials
ALS
reldesemtiv
cardiomyopathy
aficamten
Apellis’ immune system drug hits a setback in ALS
BioPharma Dive
Mon, 04/24/23 - 10:12 am
Apellis Pharmaceuticals
clinical trials
ALS
pegcetacoplan
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »